Nuwellis Inc Dossier - Source-backed chat

Nuwellis Inc

NUWENASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.45

Intrinsic Value $0.87median of 2 methodsbased on filings through 31 Mar 2026

Market Price $0.75Price as of 1 Oct 2026

UndervaluedIntrinsic value is 16% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.4M

Enterprise Value $295.2K

Shares Outstanding 3.2M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nuwellis is showing early signs of commercial execution following its 2025 strategic reset, highlighted by a 26% year-over-year revenue increase in Q1 2026 and gross margin expansion to 70.1% driven by contract manufacturing. However, the company continues to face severe capital constraints, relying on frequent dilutive equity offerings (such as the $6.0 million public offering closed in June 2026) to fund operations. With a leadership transition underway as Michael McCormick takes over as CEO on June 30, 2026, investors should maintain a Hold stance until the company establishes a sustainable path to cash-flow break-even.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0320%

Commercial adoption stalls, and the company fails to raise sufficient capital on acceptable terms. Severe dilution from warrant exercises and public offerings continues to depress the share price, or the company is forced to delay or scale back operations due to liquidity shortfalls.

Base CaseCentral scenario

$0.1455%

Nuwellis maintains moderate double-digit revenue growth and stable gross margins around 70% through contract manufacturing. However, high operating expenses from commercial expansion continue to generate net losses, requiring ongoing dilutive capital raises that cap equity upside.

Bull CaseUpside scenario

$0.3025%

Accelerated clinical adoption of the Aquadex SmartFlow system in pediatric and adult heart failure segments, combined with successful integration of Rendiatech's automated kidney-function monitoring, drives rapid revenue growth and operating leverage, leading to cash-flow break-even without further dilutive financing.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong Q1 2026 revenue growth of 26% year-over-year, driven by robust console placements and circuit utilization.
Significant gross margin expansion to 70.1% reflecting the successful transition to contract manufacturing with KDI Precision Manufacturing.
Strategic expansion of the cardiorenal portfolio through the acquisition of Rendiatech, adding automated kidney-function monitoring capabilities.

Key Investment Risks

Severe going concern risk with historically limited cash runway, requiring frequent dilutive equity offerings.
High concentration of revenue on a single product platform (the Aquadex System).
Execution risk associated with the upcoming transition to new CEO Michael McCormick on June 30, 2026.

Thesis Invalidation Triggers

Failure to secure additional financing leading to a cessation or material reduction of operations.
A sharp decline in quarterly console placements or circuit sales indicating stalled clinical adoption.
Inability to successfully integrate and commercialize the acquired Rendiatech technology.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.